skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New and emerging therapies for the treatment of rheumatoid arthritis

Review

(3709) Views  (1438) Full article downloads

Authors: Michael G Feely

Published Date July 2010 Volume 2010:2 Pages 35 - 43
DOI: http://dx.doi.org/10.2147/OARRR.S6868

Michael G Feely
Division of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA

Abstract: The introduction of tumor necrosis factor (TNF) inhibitors in the late 1990s ­significantly changed the therapeutic approach for rheumatoid arthritis (RA). With the approval of subsequent TNF inhibitors as well as other biologic agents effective in the management of RA, the treatment paradigm has become increasingly complex. This review examines the current literature regarding the efficacy and toxicity of these and other new anti-rheumatic therapies and discusses effective therapeutic strategies for their use.

Keywords: biologics, tumor necrosis factor inhibitors, DMARDs, infliximab, etancercept, adalimumab, golimumab, certolizumab, abatacept, rituximab, tocilizumab







Readers of this article also read:

Rheumatoid arthritis: Disease or syndrome?
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis
Intrasound therapy in tendon healing: is intensity a factor?
Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
Certolizumab in the long-term treatment of rheumatoid arthritis
The epidemiology and treatment of gout
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
Rheumatoid arthritis-associated interstitial lung disease
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio